A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2024 Diabetes Prevention Awareness Center.